Wenhua Yu Ph.D. (Jocelyn)

Dr. Wenhua Yu (Jocelyn) is a seasoned intellectual property (IP) attorney with a focus on the life sciences industry. With more than 12 years of practice, she assists clients — ranging from biotech start-ups to multinational pharmaceutical companies — in maximizing IP protection and leveraging IP rights to strengthen business strategies and transactions. Jocelyn's experience spans global patent strategy and portfolio development, IP due diligence, and partnership negotiations.

Jocelyn concentrates on crafting tailored IP and patent strategies, working closely with scientific teams to align patenting efforts with therapeutic pipeline development. Her deep technical knowledge covers immunotherapies (e.g., mAbs, multispecifics, T-cell engagers), gene and cell therapies (e.g., CAR-T, CRISPR), vaccines, small-molecule therapeutics, conjugated therapeutics (e.g., ADCs, AOCs, radionuclide conjugates), and manufacturing and delivery technologies (e.g., LNPs, AAVs). She has conducted extensive due diligence investigations and has provided legal opinions to support research and development (R&D), IP, and business strategies for industry leaders such as BMS/Celgene, Merck & Co., and Johnson & Johnson and has worked on several commercial products.

In addition to her patent practice, Jocelyn has more than eight years of experience advising clients on technology transaction and partnership strategies, including structuring, negotiating, and preparing licensing and collaboration agreements for biotech and pharmaceutical companies. She also counsels clients on post-execution relationship management, investigation, and resolution of IP-related disputes. Jocelyn has represented clients in cross-border transactions between the United States and Asian markets, working with organizations such as Incyte Corporation, Shanghai Junshi, and Shanghai Jemincare.